NASDAQ:ILMN - Illumina Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Illumina, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $295.94 -4.52 (-1.50 %) (As of 02/24/2020 07:25 AM ET) Add Compare Today's Range$294.79Now: $295.94▼$301.4350-Day Range$290.07MA: $312.20▼$335.5352-Week Range$263.30Now: $295.94▼$380.76Volume722,473 shsAverage Volume1.39 million shsMarket Capitalization$43.50 billionP/E Ratio43.84Dividend YieldN/ABeta1.12 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as enables the detection of known genetic markers on a single array. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Analytical instruments Sub-IndustryLife Sciences Tools & Services SectorMedical Current SymbolNASDAQ:ILMN Previous Symbol CUSIP45232710 CIK1110803 Webhttp://www.illumina.com/ Phone858-202-4500Debt Debt-to-Equity Ratio0.40 Current Ratio6.69 Quick Ratio6.15Price-To-Earnings Trailing P/E Ratio43.84 Forward P/E Ratio43.14 P/E Growth2.8 Sales & Book Value Annual Sales$3.54 billion Price / Sales12.28 Cash Flow$8.23 per share Price / Cash Flow35.95 Book Value$31.38 per share Price / Book9.43Profitability EPS (Most Recent Fiscal Year)$6.57 Net Income$1.00 billion Net Margins28.27% Return on Equity22.34% Return on Assets13.56%Miscellaneous Employees7,700 Outstanding Shares147,000,000Market Cap$43.50 billion Next Earnings Date4/23/2020 (Estimated) OptionableOptionable Receive ILMN News and Ratings via Email Sign-up to receive the latest news and ratings for ILMN and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:ILMN Rates by TradingView Illumina (NASDAQ:ILMN) Frequently Asked Questions What is Illumina's stock symbol? Illumina trades on the NASDAQ under the ticker symbol "ILMN." How were Illumina's earnings last quarter? Illumina, Inc. (NASDAQ:ILMN) announced its quarterly earnings results on Wednesday, January, 29th. The life sciences company reported $1.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.58 by $0.12. The life sciences company had revenue of $953 million for the quarter, compared to analysts' expectations of $950.16 million. Illumina had a net margin of 28.27% and a return on equity of 22.34%. Illumina's quarterly revenue was up 9.9% on a year-over-year basis. During the same quarter in the previous year, the company earned $1.32 earnings per share. View Illumina's Earnings History. When is Illumina's next earnings date? Illumina is scheduled to release their next quarterly earnings announcement on Thursday, April 23rd 2020. View Earnings Estimates for Illumina. What guidance has Illumina issued on next quarter's earnings? Illumina issued an update on its FY20 earnings guidance on Wednesday, January, 29th. The company provided earnings per share guidance of $6.80-7.00 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $6.98. The company issued revenue guidance of $3.86-3.93 billion, compared to the consensus revenue estimate of $3.92 billion. What price target have analysts set for ILMN? 15 analysts have issued 12-month price objectives for Illumina's stock. Their forecasts range from $280.00 to $380.00. On average, they anticipate Illumina's share price to reach $334.71 in the next year. This suggests a possible upside of 13.1% from the stock's current price. View Analyst Price Targets for Illumina. What is the consensus analysts' recommendation for Illumina? 15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Illumina in the last year. There are currently 2 sell ratings, 2 hold ratings and 11 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Illumina. What are Wall Street analysts saying about Illumina stock? Here are some recent quotes from research analysts about Illumina stock: 1. According to Zacks Investment Research, "Over the past year, Illumina’s shares have outperformed the industry it belongs to. It is encouraging to note that revenues grew across the company’s high and low throughput categories. Illumina continues with its robust performance across a broad range of sequencing applications. NovaSeq outpaced HiSeq X to become the most sequencing data generating platform, repeating its past performance on an annualized basis. The launch of AncestryHealth Plus and the partnership with QIAGEN N.V, the Broad Institute of MIT and Harvard in the third quarter also buoy optimism. It posted solid results in the third quarter of 2019, with earnings and revenues beating the Zacks Consensus Estimate. On the flip side, contraction in both research and development expenses and selling, general & administrative expenses are concerning for the company." (1/20/2020) 2. Canaccord Genuity analysts commented, "We don’t believe an ultra-premium multiple is now justified for a company looking to grow +6% on the top and bottom lines, which now seem more vulnerable to large misses. What’s more, we lack visibility to 2020 or 2021 growth rates given a wide range of moving parts. We would look to get more constructive if our concerns prove to be transitory, or if ILMN announces the $100 genome at a price point that would meaningfully accelerate its top line and not add further headwinds to its gross, operating or net income margins. ILMN is working hard to drive down the cost of sequencing to be able to usher in the eagerly awaited $100 genome. DTC troubles. On the call, Illumina CEO Francis deSouza indicated he expects a DTC reacceleration “in the coming years,” which to us doesn’t imply a recovery in 2020." (7/30/2019) Has Illumina been receiving favorable news coverage? News articles about ILMN stock have been trending very negative on Monday, according to InfoTrie. InfoTrie identifies negative and positive news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Illumina earned a media sentiment score of -3.0 on InfoTrie's scale. They also assigned news headlines about the life sciences company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the near future. View News Stories for Illumina. Are investors shorting Illumina? Illumina saw a decrease in short interest in January. As of January 31st, there was short interest totalling 3,220,000 shares, a decrease of 10.8% from the January 15th total of 3,610,000 shares. Based on an average daily trading volume, of 957,800 shares, the days-to-cover ratio is presently 3.4 days. Approximately 2.2% of the shares of the stock are short sold. View Illumina's Current Options Chain. Who are some of Illumina's key competitors? Some companies that are related to Illumina include Thermo Fisher Scientific (TMO), Agilent Technologies (A), Mettler-Toledo International (MTD), Waters (WAT), Bio-Rad Laboratories (BIO), PerkinElmer (PKI), Charles River Laboratories Intl. (CRL), BIO-TECHNE (TECH), Bruker (BRKR), Cambrex (CBM), Luminex (LMNX), Pacific Biosciences of California (PACB), Fluidigm (FLDM), Harvard Bioscience (HBIO) and aTyr Pharma (LIFE). What other stocks do shareholders of Illumina own? Based on aggregate information from My MarketBeat watchlists, some companies that other Illumina investors own include NVIDIA (NVDA), Alibaba Group (BABA), Netflix (NFLX), Walt Disney (DIS), Tesla (TSLA), Baidu (BIDU), Visa (v), Micron Technology (MU), Adobe (ADBE) and Gilead Sciences (GILD). Who are Illumina's key executives? Illumina's management team includes the folowing people: Mr. Jay T. Flatley, Exec. Chairman (Age 66)Mr. Francis A. deSouza, CEO, Pres & Director (Age 48)Mr. Sam A. Samad, CFO & Sr. VP (Age 49)Mr. Omead Ostadan, Sr. VP of Products, Marketing & Strategic Planning (Age 47)Ms. Aimee L. Hoyt, Chief People Officer & Sr. VP (Age 48) Who are Illumina's major shareholders? Illumina's stock is owned by many different of institutional and retail investors. Top institutional investors include Baillie Gifford & Co. (12.07%), Capital Research Global Investors (5.43%), Edgewood Management LLC (3.25%), Jennison Associates LLC (2.74%), Sands Capital Management LLC (2.33%) and Geode Capital Management LLC (1.62%). Company insiders that own Illumina stock include A Blaine Bowman, Aimee L Hoyt, Charles Dadswell, Frances Arnold, Francis A Desouza, Jay T Flatley, Karin Eastham, Marc Stapley, Mostafa Ronaghi, Oene Mark Van, Omead Ostadan, Phillip G Febbo, Robert P Ragusa, Robert S Epstein, Sam Samad and Susan H Tousi. View Institutional Ownership Trends for Illumina. Which major investors are selling Illumina stock? ILMN stock was sold by a variety of institutional investors in the last quarter, including Jennison Associates LLC, First Hawaiian Bank, Fred Alger Management LLC, Jackson Square Partners LLC, First Trust Advisors LP, Sands Capital Management LLC, Janus Henderson Group PLC and FIL Ltd. Company insiders that have sold Illumina company stock in the last year include Aimee L Hoyt, Charles Dadswell, Frances Arnold, Francis A Desouza, Jay T Flatley, Mostafa Ronaghi, Oene Mark Van, Omead Ostadan, Phillip G Febbo, Robert P Ragusa, Robert S Epstein, Sam Samad and Susan H Tousi. View Insider Buying and Selling for Illumina. Which major investors are buying Illumina stock? ILMN stock was acquired by a variety of institutional investors in the last quarter, including Alliancebernstein L.P., Baillie Gifford & Co., Artisan Partners Limited Partnership, Massachusetts Financial Services Co. MA, Sumitomo Mitsui Trust Holdings Inc., Nikko Asset Management Americas Inc., Capital Research Global Investors and Wellington Shields & Co. LLC. View Insider Buying and Selling for Illumina. How do I buy shares of Illumina? Shares of ILMN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is Illumina's stock price today? One share of ILMN stock can currently be purchased for approximately $295.94. How big of a company is Illumina? Illumina has a market capitalization of $43.50 billion and generates $3.54 billion in revenue each year. The life sciences company earns $1.00 billion in net income (profit) each year or $6.57 on an earnings per share basis. Illumina employs 7,700 workers across the globe.View Additional Information About Illumina. What is Illumina's official website? The official website for Illumina is http://www.illumina.com/. How can I contact Illumina? Illumina's mailing address is 200 ILLUMINA WAY, SAN DIEGO CA, 92122. The life sciences company can be reached via phone at 858-202-4500 or via email at [email protected] MarketBeat Community Rating for Illumina (NASDAQ ILMN)Community Ranking: 2.6 out of 5 ( )Outperform Votes: 998 (Vote Outperform)Underperform Votes: 887 (Vote Underperform)Total Votes: 1,885MarketBeat's community ratings are surveys of what our community members think about Illumina and other stocks. Vote "Outperform" if you believe ILMN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ILMN will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/24/2020 by MarketBeat.com StaffFeatured Article: Analyst Ratings Trading
